

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INTELGENX CORP.
Petitioner

v.

ICOS CORP.
Patent Owner

Case IPR: Unassigned

U.S. Patent No. 6,943,166 B2

INTELGENX CORP'S EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

IntelGenX Corp's Exhibit List for
Inter Partes Review of U.S. Patent No. 6,943,166

<i>IntelGenX Exhibit #</i>	<i>Description</i>
1001	Pullman, W.E., <i>et al.</i> , "Compositions Comprising Phosphodiesterase [Inhibitors] for the Treatment of Sexual Dysfunction," U.S. Patent No. 6,943,166 (filed on April 26, 2000; issued September 13, 2005)
1002	Daugan, A.C-M., "Use of cGMP-Phosphodiesterase Inhibitors to Treat Impotence," Int'l Pub. No. WO 97/03675 (filed July 11, 1996; published February 6, 1997)
1003	"Center for Drug Evaluation and Research," Approval Package for VIAGRA, Approval Date March 27, 1998 ("SNDA")
1004	"Center for Drug Evaluation and Research," Approval Package for VIAGRA, Approval Date March 27, 1998, pp. i-xxx, 99-103, 183-188 ("SNDA Condensed")
1005	Declaration of Wayne J.G. Hellstrom, M.D., FACS
1006	Dr. Wayne J.G. Hellstrom's <i>Curriculum Vitae</i>
1007	Declaration of Douglas Reid Patterson, D.V.M, PH.D
1008	Dr. Douglas Reid Patterson's <i>Curriculum Vitae</i>
1009	Boolell, M., <i>et al.</i> , "Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction," <i>Int'l J. Impot. Res.</i> , 8:47-52 (1996)
1010	Rosen, R.C., <i>et al.</i> , "The International Index of Erectile Function (IIEF): A Multidimensional Scale for Assessment of Erectile Dysfunction," <i>Urology</i> , 49:822-830 (1997)
1011	Laumann, E.O., <i>et al.</i> , "Sexual Dysfunction in the United States," <i>JAMA</i> , 281:537-544 (1999)
1012	Halvorsen, J.G., and Metz, M.E., "Sexual Dysfunction, Part I: Classification, Etiology, And Pathogenesis," <i>JABFP</i> , 5:51-61 (1992)

IntelGenX Corp's Exhibit List for
Inter Partes Review of U.S. Patent No. 6,943,166

<i>IntelGenX Exhibit #</i>	<i>Description</i>
1013	Goldstein, I., <i>et al.</i> , "Oral Sildenafil in the Treatment of Erectile Dysfunction," <i>N. Engl. J. Med.</i> , 338:1397-1404 (1998)
1014	Terrett, N.K., <i>et al.</i> , "Sildenafil (VIAGRA TM), A Potent and Selective Inhibitor of Type 5 cGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction," <i>Bioorg. Med. Chem. Lett.</i> , 6:1819-1824 (1996)
1015	Daugan, A.C-M., "Tetracyclic Derivatives, Process of Preparation and Use," Int'l Pub. No. WO 95/19978 (filed Jan. 19, 1995; published July 27, 1995)
1016	VIAGRA [®] Approved Label, 69-5485-00-2, Revised November 1998, downloaded from the Food and Drug Administration website http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/viagralabel2.pdf , last accessed February 18, 2016
1017	Licht, M.R., "Sildenafil (Viagra) for treating male erectile dysfunction," <i>Curr. Drug Ther.</i> , 65:301-304 (1998)
1018	Gingell, C.J.C., <i>et al.</i> , "A New Oral Treatment for Erectile Dysfunction: A Double-Blind, Placebo-Controlled, Once Daily Dose Response Study," <i>J. Urology</i> , 155(Suppl 5):495A, Abstract No. 738 (1996)
1019	de Mey, C., "Opportunities for the Treatment of Erectile Dysfunction by Modulation of the NO Axis-Alternatives to Sildenafil Citrate," <i>Curr. Med. Res. Opin.</i> , 14:187-202 (1998)
1020	"Lilly/ICOS Joint Venture's PDE5 to Treat Sexual Dysfunction," <i>Worldwide Biotech</i> , 11(10), pp. 1-2, November 1998
1021	Michaels, P., "Biotech's Drug Pipeline Ready To Rupture," <i>The New America, Investor's Business Daily</i> , p. A7, April 23, 1999

IntelGenX Corp's Exhibit List for
Inter Partes Review of U.S. Patent No. 6,943,166

<i>IntelGenX Exhibit #</i>	<i>Description</i>
1022	Edelhart, C., "Lilly venture to create impotency pill, Firm will team up with drugmaker in Seattle to create drug to rival Viagra," <i>The Indianapolis Star</i> , pp. D1-D2, October 2, 1998
1023	COLOR ATLAS OF PHARMACOLOGY, pp. 44-57 (Lüllmann, H., <i>et al.</i> , eds., 1993)
1024	File History for U.S. Patent No. 6,943,166
1025	Viagra Approval Letter, Department of Health & Human Services, NDA 20-895, March 27, 1998
1026	Sybertz, E., and Czarniecki, M., "Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential," <i>Expert Opin. Ther. Pat.</i> , 7:631-639 (1997)
1027	File History for U.S. Patent No. 7,182,958
1028	Padma-Nathan, H., "Efficacy and Tolerability of Tadalafil, a Novel Phosphodiesterase 5 Inhibitor, in Treatment of Erectile Dysfunction," <i>Am. J. Cardiol.</i> , 92:19M-25M (2003)
1029	CIALIS [®] Approved Label, Reference ID: 3820620, Revised September 2015, downloaded from the Food and Drug Administration website http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021368s026lbl.pdf , last accessed February 18, 2016
1030	Nies, A.S., "Principles of Therapeutics" in GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, Ch. 4, pp. 62-83 (Gilman, A.G., <i>et al.</i> , eds., 8 th Ed. 1990)
1031	Babb, J., <i>et al.</i> , "Cancer Phase I Clinical Trials: Efficient Dose Escalation with Overdose Control," <i>Statist. Med.</i> , 17:1103-1120 (1998)

IntelGenX Corp's Exhibit List for
Inter Partes Review of U.S. Patent No. 6,943,166

<i>IntelGenX Exhibit #</i>	<i>Description</i>
1032	Oates, J.A. and Wilkinson, G.R., "Principles of Drug Therapy," in HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, Ch. 66, pp. 393-412 (Isselbacher, K.J., <i>et al.</i> , Eds., 13 th Ed. 1994)
1033	THE MERCK MANUAL OF MEDICAL INFORMATION, Ch. 5, pp. 23-27 (Berkow, R., <i>et al.</i> , Eds., Home Edition 1997)
1034	Bourne, H.R. and Roberts, J.M., "Drug Receptors & Pharmacodynamics," in BASIC & CLINICAL PHARMACOLOGY, Ch. 2, pp. 9-32 (Katzung, B.G., ed., 6 th Ed. 1995)
1035	Graham, M.A., and Workman, P., "The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: Critical evaluation and recommendations for future studies," <i>Ann. Oncol.</i> , 3:339-347 (1992)
1036	Piantadosi, S., and Liu, G., "Improved Designs for Dose Escalation Studies Using Pharmacokinetic Measurements," <i>Stat. Med.</i> , 15:1605-1618 (1996)
1037	Rinaldi, D.A., <i>et al.</i> , "Initial Phase I Evaluation of the Novel Thymidylate Synthase Inhibitor, LY231514, Using the Modified Continual Reassessment Method for Dose Escalation," <i>J. Clin. Oncol.</i> , 13:2842-2850 (1995)
1038	"What's hot Impotency drugs," <i>Discount Store News</i> , p. 35, June 22, 1998
1039	Cialis Approval Letter- Department of Health & Human Services, NDA 21-368, November 21, 2003, downloaded from the Food and Drug Administration website http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21368ltr.pdf , last accessed February 18, 2016

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.